Form 4 for EW Edwards Lifesciences
Accepted 2026-05-12 16:55:45 ET · period of report 2026-05-11 · accession 0001225208-26-005172 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-12 16:55 | 2026-05-11 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | +47.2K | 157.5K | +43% | $0 |
| DT | 2026-05-12 16:55 | 2026-05-11 | EW | Zovighian Bernard J | CEO, Dir | F - Tax | $79.96 | -26.2K | 125.8K | -17% | -$2.09M |
| DT | 2026-05-12 16:55 | 2026-05-12 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | -26.6K | 99.2K | -21% | $0 |
| DTI | 2026-05-12 16:55 | 2026-05-12 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | +26.6K | 48.4K | +122% | $0 |
| DMTI | 2026-05-12 16:55 | 2026-05-12 | EW | Zovighian Bernard J | CEO, Dir | S - Sale+OE | $77.93 | -36.4K | 12.0K | -75% | -$2.83M |
| DT | 2026-05-12 16:55 | 2026-05-11 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | -47.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | M | A | 47,207 | $0.00 | 157,491.65 | D | — | — | (F1) On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. (F1) On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. |
| 2 | Common | Common Stock | 2026-05-11 | F | D | 26,198 | $79.96 | 125,804.65 | D | — | — | |
| 3 | Common | Common Stock | 2026-05-12 | G | D | 26,640 | $0.00 | 99,164.65 | D | — | — | |
| 4 | Common | Common Stock | 2026-05-12 | G | A | 26,640 | $0.00 | 48,390.55 | I By Trust | — | — | |
| 5 | Common | Common Stock | 2026-05-12 | S | D | 845 | $78.40 | 47,545.55 | I By Trust | — | — | (F2) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-05-12 | S | D | 35,506 | $77.92 | 12,039.55 | I By Trust | — | — | (F2) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Derivative | Performance Rights | 2026-05-11 | M | D | 47,207 | $0.00 | 0 | D | — · 2026-05-11 to — | 47,207 Common Stock | (F1) On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. (F5) These Performance Rights expire on May 10, 2030. |